SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Celgene-CELG
An SI Board Since August 1996
Posts SubjectMarks Bans Symbol
804 71 0 CELG
Emcee:  rkrw Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
554The dosing issue is pretty significant. One of the issues that has caused weakneBiomaven-7/9/2001
553NEW YORK, July 9 /PRNewswire/ -- Cancer patients are at high risk of potentiallynigel bates-7/9/2001
552WARREN, N.J., July 9 /PRNewswire/ -- Celgene Corporation (Nasdaq: CELG - news) -nigel bates-7/9/2001
551J.D. & Miljenko; Thanks, for your kind wishes! MikeMike K-6/27/2001
550WARREN, N.J., June 27 /PRNewswire/ -- Celgene Corporation (Nasdaq: CELG - news) nigel bates-6/27/2001
549Genta candidate is not serious T competitor. Also, it will compete with Rituxan Miljenko Zuanic-6/25/2001
548Cancer Patients Ahead of FDA on Thalidomide Use Monday, June 25, 2001 By Jerrsim1-6/25/2001
547Any comments on how Thalidomid compares to Genasense trials? Monday June 25, Extra Pale-6/25/2001
546Mike, I am glad that T work well for you. I am T believer. However, T is veryMiljenko Zuanic-6/21/2001
545Wishing you the very best, and I pray that this line of defense works for you.jayhawk969-6/21/2001
544As a myeloma patient let me chime in with my own anecdotal experience with thaliMike K-6/21/2001
543Miljenko, approval for first line therapy is questionable IMO, but this has not Vector1-6/21/2001
542<<It is clear to me that thal will get approval for MM. At that point saleMiljenko Zuanic-6/21/2001
541Merrill Lynch Global Securities Research (CELG; $27.15; D-2-1-9) Dec01E $0.3Vector1-6/21/2001
540The MS take is that this is old news (true). Here's their report: ragingbBiomaven-6/21/2001
539Morgan Stanley to the rescue. they like it (gee, what a surprise)Ben Wa-6/21/2001
538The thrombosis happened in a combo trial with dexamethasone. Here's the NEJBiomaven-6/21/2001
537The patients experiencing thrombosis seemed to be a subset that would naturally Harold Engstrom-6/21/2001
536Celgene post #26947 on Yahoo documents the NEJM article.Larry Liebman-6/21/2001
535This is what Briefing says it says. Not pretty >><i>10:34 ET Celgentom pope-6/21/2001
534Deep Venous Thrombosis and Thalidomide Therapy for Multiple Myeloma, in NEJM curpaul ta-6/21/2001
533Geraldine's selling!Ben Wa-6/21/2001
532Geraldine's selling! She missed the taxi to her presentation. She's faBen Wa-6/21/2001
531Well, sell my news! I guess they're not getting the banner OR the sweatshirDoc Bones-6/21/2001
530From Briefing. Anybody have any news? <i>10:01 ET Celgene (CELG) 26.68 -4tom pope-6/21/2001
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News